Published in:
01-03-2020 | Rectal Cancer | Original Article
Short- and long-term outcomes of robotic surgery for rectal cancer: a single-center retrospective cohort study
Authors:
Hidetoshi Katsuno, Tsunekazu Hanai, Koji Masumori, Yoshikazu Koide, Hiroshi Matsuoka, Yosuke Tajima, Tomoyoshi Endo, Masahiro Mizuno, Yongchol Chong, Kotaro Maeda, Ichiro Uyama
Published in:
Surgery Today
|
Issue 3/2020
Login to get access
Abstract
Purpose
This study aimed to clarify the short- and long-term outcomes of robotic surgery with or without lateral lymph node dissection (LLND) for rectal cancer at Fujita Health University Hospital, Aichi, Japan, during a self-pay period.
Methods
We retrospectively evaluated 115 consecutive patients who underwent robotic surgery for rectal cancer between September 2009 and March 2018, with a median follow-up period of 48 months. Total mesorectal excision was completed by two certified surgeons using a da Vinci S, Si, or Xi Surgical System with an entirely robotic single-docking technique. The surgical and pathological outcomes, morbidity, and oncological results were examined.
Results
Lateral lymph node dissection was performed in 26 patients (22.6%). Neither conversion to open surgery nor perioperative blood transfusion occurred. Ten patients (8.7%) experienced Clavien–Dindo grade III postoperative complications. Pathologically, both the distal and radial margins were negative in all cases. The 5-year relapse-free survival rates for stages I, II, III, and IV were 93.5%, 100%, 83.8%, and not reached, respectively.
Conclusions
Even in the period before coverage by the health insurance system, robotic surgery for rectal cancer performed by experienced surgeons was safe and technically feasible, with favorable perioperative results and long-term oncological outcomes, including rates of the relapse-free survival.